To view this email as a web page, click here.
 
Nearly 25% of pneumococcal disease still caused by PCV13 serotypes, shows new study
image description here Despite the success of the 13-valent pneumococcal conjugate vaccine (PCV13), there is still much work to be done: A recent study shows that it protects against just 13 of the more than 90 serotypes of pneumococcal bacteria that can cause disease.

Find out more.
 
Have a puzzling case?
image description here Have a puzzling pediatric case that you'd like to share with your fellow readers? We're looking for stories about intriguing diagnoses that have stumped the experts! If you’re interested, please contact cradwan@mmhgroup.com for submission guidelines.

 
What to consider when treating warts
image description here Many treatments for warts are destructive and painful, and are more likely to cause complications than the warts. A pediatric dermatologist advises what to do-or not do-for common warts.

Find out more.
 
IN CASE YOU MISSED IT
 
6 phases of return-to-play following a concussion
Minority groups face higher prevalence, more ED visits for asthma
Why is AI the big thing now?
 
ADVERTISEMENT
50% of amblyopia cases are still being missed!
What is the cost of missing an amblyopia? The cost to the child is lifelong vision impairment. Six years after the 2012 instrument-based vision screening policy, half are still missed! Why? Click here
 
CONTEMPORARY PEDIATRICS VIDEO
 
Are kids with ADHD getting followup care in Medicaid?
image description here For Contemporary Pediatrics, Dr Bobby Lazzara discusses a study published by Department of Health and Human Services that examined whether children enrolled with Medicaid who had an ADHD diagnosis received the recommended followup care.
 
ADVERTISEMENT
image description here New on Medgizmos: MeHealth, an online tool for diagnosing and managing ADHD is now free! Learn more...
 
JOB OPPORTUNITIES
 
NY-Chinatown Global Pediatrics
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.